Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 11/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 9/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21510292 | 0.83 | NTRK1 (0.53) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16947001 | 0.83 | IRAK4 (0.42) | JAK2NTRK1NTRK3NTRK2 | |
| SCHEMBL16947090 | 0.80 | NTRK1 (0.41) | JAK2NTRK1NTRK3NTRK2 | |
| SCHEMBL21076797 | 0.80 | NTRK1 (0.41) | JAK2NTRK1NTRK3NTRK2 | |
| SCHEMBL16946999 | 0.77 | CXCR3 (0.39) | JAK2NTRK1NTRK3 | |
| SCHEMBL21942124 | 0.76 | RBP4 (0.36) | JAK2NTRK1NTRK3NTRK2 | |
| SCHEMBL23473891 | 0.75 | NTRK1 (0.38) | JAK2NTRK1NTRK3 | |
| SCHEMBL16946747 | 0.75 | NTRK1 (0.39) | JAK2NTRK1NTRK3NTRK2ALK | |
| SCHEMBL22201908 | 0.75 | NTRK1 (0.39) | JAK2NTRK1NTRK3NTRK2ALK | |
| SCHEMBL16947088 | 0.75 | RBP4 (0.39) | JAK2NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358973-B2 | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20210171542-A1 | DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-06-10 | — | — | US | disclosed |
| EP-3770161-A1 | DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019201131-A1 | DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358973-B2 | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity | MAP2K3, MAP2K2, MAP2K7 | JAK2 191/4885NTRK1 611/4885NTRK3 1391/4885 |
| US-20210171542-A1 | DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K7, MAP2K2, MAP2K1 | JAK2 153/4885NTRK1 705/4885NTRK3 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.